mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin has been researched along with levodopa in 1 studies
| Studies (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Trials (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Recent Studies (post-2010) (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Studies (levodopa) | Trials (levodopa) | Recent Studies (post-2010) (levodopa) |
|---|---|---|---|---|---|
| 69 | 0 | 42 | 17,774 | 1,900 | 4,946 |
| Protein | Taxonomy | mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin (IC50) | levodopa (IC50) |
|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | 0.5939 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 0.5939 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 2.88 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 3.729 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.146 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.258 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dixit, A; Mishra, M; Prakash, O; Singh, MP; Singh, PK; Srivastava, G; Verma, D | 1 |
1 other study(ies) available for mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin and levodopa
| Article | Year |
|---|---|
Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Homeodomain Proteins; Levodopa; Male; Maneb; Metalloporphyrins; Mice; Microglia; Minocycline; Mitochondria; Paraquat; Parkinson Disease, Secondary; Proteome; Stathmin; Superoxide Dismutase | 2013 |